Success Metrics

Clinical Success Rate
80.6%

Based on 25 completed trials

Completion Rate
81%(25/31)
Active Trials
2(5%)
Results Posted
16%(4 trials)
Terminated
6(16%)

Phase Distribution

Ph not_applicable
2
5%
Ph phase_2
16
43%
Ph phase_3
5
14%
Ph phase_1
14
38%

Phase Distribution

14

Early Stage

16

Mid Stage

5

Late Stage

Phase Distribution37 total trials
Phase 1Safety & dosage
14(37.8%)
Phase 2Efficacy & side effects
16(43.2%)
Phase 3Large-scale testing
5(13.5%)
N/ANon-phased studies
2(5.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.1%

25 of 32 finished

Non-Completion Rate

21.9%

7 ended early

Currently Active

2

trials recruiting

Total Trials

37

all time

Status Distribution
Active(2)
Completed(25)
Terminated(7)
Other(3)

Detailed Status

Completed25
Terminated6
Recruiting2
unknown2
Suspended1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
2
Success Rate
80.6%
Most Advanced
Phase 3

Trials by Phase

Phase 114 (37.8%)
Phase 216 (43.2%)
Phase 35 (13.5%)
N/A2 (5.4%)

Trials by Status

suspended13%
withdrawn13%
completed2568%
terminated616%
recruiting25%
unknown25%

Recent Activity

2 active trials
Showing 5 of 37
completedphase_1

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00646230
recruitingphase_1

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539
recruitingphase_1

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048
completedphase_1

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

NCT06181760
completedphase_2

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

NCT00003601
View all 37 trials

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT00646230Phase 1

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Completed
NCT06922539Phase 1

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

Recruiting
NCT04234048Phase 1

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Recruiting
NCT06181760Phase 1

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

Completed
NCT00003601Phase 2

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Completed
NCT01187810Phase 1

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

Terminated
NCT00546455Phase 2

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Suspended
NCT02495415Phase 2

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Unknown
NCT00004154Phase 3

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Completed
NCT01479192Phase 3

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Terminated
NCT00006471Phase 2

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed
NCT00003075Phase 3

Fenretinide in Treating Patients With Cervical Neoplasia

Completed
NCT00006080Phase 2

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Completed
NCT00104923Phase 1

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Completed
NCT02141958Phase 1

Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis

Completed
NCT00080899Phase 2

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Completed
NCT00288067Phase 1

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Terminated
NCT00003250Phase 1

Fenretinide in Treating Patients With Solid Tumors

Completed
NCT00053326Phase 2

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

Completed
NCT00387504Phase 1

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Completed

Drug Details

Intervention Type
DRUG
Total Trials
37